Edwards Lifesciences CorporationEWNYSE
LOADING
|||
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-12.28%
↓ 109% below average
Average (39q)
129.77%
Historical baseline
Range
High:3900.00%
Low:-140.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -12.28% |
| Q2 2025 | -6.56% |
| Q1 2025 | -6.15% |
| Q4 2024 | -87.35% |
| Q3 2024 | 742.62% |
| Q2 2024 | 5.17% |
| Q1 2024 | -4.92% |
| Q4 2023 | -3.17% |
| Q3 2023 | 23.53% |
| Q2 2023 | -8.93% |
| Q1 2023 | -13.85% |
| Q4 2022 | 18.18% |
| Q3 2022 | -15.38% |
| Q2 2022 | 8.33% |
| Q1 2022 | 11.11% |
| Q4 2021 | -1.82% |
| Q3 2021 | -30.38% |
| Q2 2021 | 46.30% |
| Q1 2021 | 8.00% |
| Q4 2020 | -3.85% |
| Q3 2020 | 360.00% |
| Q2 2020 | -140.00% |
| Q1 2020 | 11.11% |
| Q4 2019 | 2.27% |
| Q3 2019 | 12.82% |
| Q2 2019 | -2.50% |
| Q1 2019 | 3900.00% |
| Q4 2018 | -97.22% |
| Q3 2018 | -20.00% |
| Q2 2018 | 36.36% |
| Q1 2018 | 484.07% |
| Q4 2017 | -79.07% |
| Q3 2017 | -6.90% |
| Q2 2017 | -19.44% |
| Q1 2017 | 44.00% |
| Q4 2016 | 13.64% |
| Q3 2016 | 10.00% |
| Q2 2016 | -9.09% |
| Q1 2016 | 0.00% |
| Q4 2015 | 22.22% |